epoetin alfa

Pfizer will present data from more than 60 abstracts at ASCO 2025, including 15 oral presentations highlighting advancements across breast, genitourinary, hematologic, thoracic, and colorectal cancers.

A decade after the first biosimilar approval, these drugs have generated $36 billion in healthcare savings, though adoption rates vary significantly across different molecules and therapeutic areas.

A comprehensive review of global Myelodysplastic Syndrome clinical trials reveals extensive research activity across G7 and E7 countries, with major pharmaceutical companies leading development efforts.

A phase 1b trial combining luspatercept and lenalidomide demonstrates safety and preliminary efficacy in patients with non-del(5q) myelodysplastic syndrome (MDS).

Bristol Myers Squibb has reported positive phase 3 trial results for Reblozyl, showing significant improvement in red blood cell transfusion independence for patients with myelodyplastic syndromes (MDS).